A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer

Clinical trial NCT05346224 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05346224
Sponsor: Shanghai Henlius Biotech
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Breast Cancer Breast Neoplasms HER2-positive Breast Cancer

Start date: 2022-04-25
Primary completion: 2024-05-15
Enrollment: 900

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.